Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Hui Huang, PhD, MBA, Sanggyu Choi, PhD, Deyanira Corzo, MD

Blood (2011) 118 (21): 1864.

https://doi.org/10.1182/blood.V118.21.1864.1864

Published: 2011

Journal Articles

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Deyanira Corzo, MD, James Reeves, MD

Blood (2011) 118 (21): 478.

https://doi.org/10.1182/blood.V118.21.478.478

Published: 2011

Journal Articles

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert M. Rifkin, MD, Nashat Y Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf A Gaffar, MD, Thomas A. Warr, MD, Rachel Neuwirth, MS, Deyanira Corzo, MD, James A Reeves, MD

Blood (2010) 116 (21): 3026.

https://doi.org/10.1182/blood.V116.21.3026.3026

Published: 2010

Journal Articles

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Lihua E Budde, MD., PhD, Andrei Shustov, MD, John M. Pagel, MD, PhD, Ted Gooley, PhD, George Oliviera, MD, Tara Chen, PharmD, Michelle Zhang, MD, Thomas A. Warr, MD, Thomas Boyd, MD, Oliver W. Press, MD, PhD, Ajay K Gopal, MD

Blood (2010) 116 (21): 2790.

https://doi.org/10.1182/blood.V116.21.2790.2790

Published: 2010

Journal Articles

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Blood (2010) 116 (21): 619.

https://doi.org/10.1182/blood.V116.21.619.619

Published: 2010

Journal Articles

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.

Lihua E. Budde, MD, PhD, Michelle M. Zhang, MD, Andrei R. Shustov, MD, John M. Pagel, MD, PhD, Thomas A. Warr, MD, FACP, Tara L Chen, PharmD, RPh, George R. Oliveira, MD, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2009) 114 (22): 3696.

https://doi.org/10.1182/blood.V114.22.3696.3696

Published: 2009

NARROW

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only